Background
==========

*S. aureus* is a highly versatile gram positive organism capable of being a commensal and causing a variety of diseases such as soft tissue infections, bacterial endocarditis, septicemia and osteomyelitis. The ability of the organism to cause a multitude of infections is probably due to the expression of myriads of different toxins, virulence factors and also cell wall adhesion proteins and staphylococcal superantigen like proteins (ssl) involved in immune-evasion. The emergence of MRSA in most countries of the world is a cause of great concern. Vancomycin resistance, in addition, has left physicians with limited treatment options \[[@B1],[@B2]\].

The distinction between HA- MRSA and CA- MRSA was clear when CA-MRSA were first reported. CA-MRSA originated with individuals in the community who had none of the risk factors from exposure to hospital environment and had distinctly different antibiotic sensitivities than the HA-MRSA which infected hospitalized patients with specific risks of infections. But in the last five years, CA-MRSA have infiltrated the hospitals and are replacing HA-MRSA, mainly in countries where the prevalence of CA-MRSA is high \[[@B3]\].

Methicillin resistance is conferred on the organism by the presence of a unique mobile genetic element called the SCC*mec* carrying the *mecA* gene. The SCC*mec* elements are divided into different types based on the nucleotide differences in two essential components, *ccr* (cassette chromosome recombinase) gene complex, represented by *ccr* genes and *mec* gene complexes. Eight major types of SCC*mec* elements were reported till recently but three more new types have been added in the past few months from bovine and human origins increasing the total to eleven SCC*mec* types \[[@B4]-[@B6]\]. HA-MRSA isolates contain mainly type I, II, and III SCC*mec* elements while CA-MRSA contain type IV and V SCC*mec* elements each of which has several variants. For instance, majority of Indian HA-MRSA collected between 2002 and 2006 contained type III or IIIA SCC*mec* elements, as previously reported \[[@B7],[@B8]\].

We reported in 2008 the presence of *PVL* positive ST22 (EMRSA-15) and ST772 (single locus variant of ST1 and belonging to CC1) as major clones in nasal swabs collected in healthy carriers in and around Bengaluru in a small number of samples \[[@B9]\]. Recently, our studies in carriers and individuals with disease from rural and urban areas of Bengaluru showed variants of EMRSA-15 clones \[[@B10]\]. Another study from a tertiary care hospital in Mumbai also demonstrated the presence of EMRSA-15 as a major clone among patients \[[@B11]\]. A second important clone is the *PVL*-positive ST772 which has been detected in and around Bengaluru, Mumbai (India), Bangladesh and Malaysia \[[@B9],[@B11]-[@B13]\]. These two dominant epidemic clones are associated with both CA- and HA-infections in India and seem to have progressively replaced the ST239 clone in hospitals \[[@B11]\].

Aim of this study was to establish the lineage of sensitive and resistant *S. aureus* strains collected from in and around Bengaluru and three other cities in India, and determine their toxins and virulence factors. In this article, MRSA and MSSA collected either from HA- and CA-infections or carriages were characterized using the microarray system developed by Clonediag® which detects 300 alleles of the *S. aureus* genome \[[@B14]\]. This characterization complemented those obtained by multi-locus sequence typing (MLST), staphylococcal protein A (*spa)* typing, pulsed field gel electrophoresis (PFGE), PCR to confirm the SCC*mec* type, toxin gene content, and antibiograms. The two already-reported ST22 and ST772 clones were detected as MSSA and MRSA. The spreading of ST8 along with an emerging clone of PVL-negative ST672 among Indian CA-MRSA is being reported in this study. The Indian MSSA clones identified were much more diverse and were different from the MRSA clones, except for ST8 and 672 which were detected in both MRSA and MSSA groups. The livestock-associated ST398 related clone (ST291) is reported for the first time in two MSSA isolates.

Results
=======

Carrier and disease *S. aureus* isolates
----------------------------------------

Carrier (38) and disease (30) isolates were collected from rural, urban out patient and urban in patient environments and analysis is presented in Table [1](#T1){ref-type="table"}.

###### 

Molecular characteristics of MSSA/MRSA clones from carriers and disease isolates

  **CC/ST**                **N (%)**                      **Carrier/Disease isolates N/N**   **MRSA N (%) {Carrier/Disease, N}**   **SCC*mec* typ*e***   ***spa* types (MRSA/MSSA)**   ***agr* type**   ***PVL* genes N (%)**   ***tst-1* N (%)**   ***egc* N (%)**   **Other genes (N)**            **Capsular type**
  ------------------------ ------------------------------ ---------------------------------- ------------------------------------- --------------------- ----------------------------- ---------------- ----------------------- ------------------- ----------------- ------------------------------ -------------------
  CC22-ST22                19 (28)                        8/11                               13 (68)                               IV                    t852 (13/0)                   I                19 (100)                0/19                19 (100)          *sec, sel* (1)                 5
  4/9                      t005 (0/5)                     *sea, seb* (1)                                                                                                                                                                                                                             
  t2986 (0/1)                                                                                                                                                                                                                                                                                        
  CC1-ST772                13 (19)                        7/6                                9 (69)                                V                     t657 (5 /1)                   II               13 (100)                0                   13 (100)          *sea, sec, sel* (5)            5
  4/5                      **t3387**^1^ (2/0)             *sea, see* (3)                                                                                                                                                                                                                             
  t1387 (1/0)              *sea* (3)                                                                                                                                                                                                                                                                 
  **t1839** (0/1)          *sea, seb* (1)                                                                                                                                                                                                                                                            
  **t1998** (0/1)          *sea, sec, sel, see* (1)                                                                                                                                                                                                                                                  
  **t3596** (1/0)                                                                                                                                                                                                                                                                                    
  t345 (0/1)                                                                                                                                                                                                                                                                                         
  CC121-ST120              7 (10)                         4/3                                0                                                           **t3204** (0/2)               IV               7 (100)                 0                   7 (100)           *sec (3), sea, seb,sec* (1)    8
  **t1999** (0/2)          *seb,sec* (1)                                                                                                                                                                                                                                                             
  t159 (0/3)                                                                                                                                                                                                                                                                                         
  ST672                    4 (6)                          2/2                                2 (50)                                V                     **t1309** (2/0)               I                0                       0                   4 (100)           *sea, seb* (1), *sea* (1)      8
  0/2                      **t3840** (0/1)                                                                                                                                                                                                                                                           
  **t3841** (0/1)                                                                                                                                                                                                                                                                                    
  CC45-ST45                4 (6)                          3/1                                0                                                           t939 (0/1)                    I ^2^            0                       0                   4 (100)           *sec, sel* (1)                 8
  **t4074** (0/2)                                                                                                                                                                                                                                                                                    
  **t3537** (0/1)                                                                                                                                                                                                                                                                                    
  CC5-ST5                  4 (6)                          4/0                                0                                                           t442 (0/3)                    II               1 (25)                  0                   4 (100)           *sea, sed, ser* (1)            5
  **t3597** (0/1)          *see, sed, ser* (1)                                                                                                                                                                                                                                                       
  *see* (1), *edinB* (1)                                                                                                                                                                                                                                                                             
  CC8-ST1208               3 (4.4)                        1/2                                3 (100)                               V                     t064 (3/0)                    I                1 (33)                  0                   0                 *sea, seb, sek, seq,see* (2)   5
  1/2                      *sea, seb, sek, seq* (1)                                                                                                                                                                                                                                                  
  ST72                     1 (1.5)                        1/0                                0                                                           t148 (0/1)                    I                1 (100)                 1 (100)             1 (100)           *sec, sel* (1)                 5
  CC30-ST30                4 (6)                          1/3                                1 (25)                                IV                    t021 (1/3)                    III              4 (100)                 0                   4 (100)           *sea, seb* (2)                 8
  1/0                      *sea* (1)                                                                                                                                                                                                                                                                 
  ST39                     1 (1.5)                        1/0                                0                                                           t096 (0/1)                    III              0                       0                   0                 *sea* (1)                       
  CC398-ST291              2 (3)                          2/0                                0                                                           t937 (0/1)                    I                0                       0                   1 (50)            *etd, edinB* (2)               5
  t3096 (0/1)                                                                                                                                                                                                                                                                                        
  CC15-ST199               2 (3)                          0/2                                0                                                           t774 (0/2)                    II               0                       0                   0                 None                           8
  ST6                      3 (4.4)                        3/0                                0                                                           t304 (0/1)                    I                0                       1 (33)              0                 *sea, sel (1)*                 8
  **t4285** (0/1)          *sea, seb, sek, seq, see*(1)                                                                                                                                                                                                                                              
  t701 (0/1)               *sel* (1)                                                                                                                                                                                                                                                                 
  ST7                      1 (1)                          1/0                                0                                                           t091 (0/1)                    I                0                       0                   0                 *sep*                          8
  **Total**                **68**                         **38/30**                          **28 (41)**                                                                                                **47 (69)**                                 **57 (84)**                                       

^1^New spa types reported to the data base; ^2^ 1 isolate is *agr* negative.

Twenty six percent of carrier isolates and sixty percent of disease isolates were MRSA. All MRSA carried SCC*mec* type IV or V. Total of 15 STs were present among all the 68 isolates characterized. All but one sequence type were present in carrier isolates. ST 22, 772, 30, 121, 1208, 199, 672, and 45 were present among disease isolates. ST 5, 6, 7, 39, 72, and 291were present only among carriers. Antibiotic sensitivity to five antibiotics -oxacillin, cefoxitin, erythromycin, gentamicin, and tetracycline were tested on all the strains (data not presented). Isolates belonging exclusively to carrier STs were sensitive to all the antibiotics tested. Predominant methicillin resistant STs were 22 (68%) and 772 (69%) along with small percentage of isolates belonging to ST30, 672 and 1208 carrying 1.5, 3.0 and 4.4 percent of isolates respectively as MRSA. Carrier MRSA isolates were limited to ST22, 772, 30 and 1208 while disease MRSA isolates in addition included ST672. All carrier and disease isolates of ST22 and 772 lineage were *PVL* and *egc* positive.

MLST types
----------

Twelve *S. aureus* CC (15 STs) were identified with three of the clones detected in more than 10% of the isolates (ST22, ST772 and ST121) (Table [1](#T1){ref-type="table"}). New or recently emerging clones were also detected (ST1208 and ST672). Figure [1](#F1){ref-type="fig"} shows the eBURST analysis and lineages of all sequence types. Details of all the STs follow as given below. CC and STs of MSSA were much more diverse than those of MRSA (12 for MSSA, 5 for MRSA). Isolates belonged to all the 4 *agr* types. New *spa* types were detected among MRSA and MSSA isolates of lineages ST672, 772, 45, 121 and 6. *PVL* genes were detected in 69% of the isolates and *egc* in 84%. Microarray analysis was performed for representative carrier and disease isolates from each sequence type to determine the virulent factors and toxins.

![**eBURST analysis of 15 STs present among the Indian *Staphylococcus aureus* collection.**](1471-2180-12-64-1){#F1}

Microarray
----------

Factors which were common to all isolates when analyzing the microarray results, were as follows: virulence factor genes- α, γ, δ haemolysins, staphylococcal complement inhibitor (*scn*), aureolysin, *sspA, sspB* and *sspP*; MSCRAMMS genes- *fnbA, fib, ebpS, vwb, sdrC*; Clumping factors A and B; *bbp* (bone sialo-protein binding protein); *map* (major histocompatibility complex class II analog protein) and immune-evasion genes- *isaB, isdA, imrP, mprF, hysA1, hysA2, set 6, ssl9* were present in all except in one isolate of ST199 and one isolate of ST22, *ssl*7 absent only in one isolate of ST121. The patterns of presence and absence of virulence and immune evasion factors strictly followed the sequence type. Carrier and disease isolates belonging to a particular ST type had the same patterns. Raw microarray data of 33 isolates is provided as an [Additional file 1](#S1){ref-type="supplementary-material"}. In a few cases where results were ambiguous, results have been confirmed with PCRs.

PFGE
----

Figure [2](#F2){ref-type="fig"}A represents PFGE patterns of one representative isolate from each ST and 2B the dendrogram of PFGE depicting the relatedness of patterns based on the similarities derived from the UPGMA and dice coefficients using the Quantity one software. All profiles were different from each other and were distinct patterns characteristic of the ST.

![**A: PFGE patterns of *SmaI* digested isolates showing different sequence types of Indian *S. aureus.* ** Lane: 1, 8,15 - NCTC8325, Lane 2 - ST22, Lane 3 - ST6, Lane 4 -- ST7, Lane 5 -- ST45, Lane 6 -- ST1208, Lane 7 -- ST72, Lane 9 -- ST672, Lane 10 -- ST199, Lane 11 -- ST772, Lane 12 -- ST5, Lane 13 -- ST30, Lane 14 -- ST121. **B**: Dendrogram of PFGE based on similarities derived from the UPGMA and dice coefficients using Quantity one software.](1471-2180-12-64-2){#F2}

CC22-ST22
---------

ST22 is the major clone detected in 28% of the isolates present in both carrier and disease isolates. Methicillin resistance was detected in 68% in both groups, and the MRSA isolates had a SCC*mec* IV element. PFGE patterns of all ST22 isolates resembled classical EMRSA-15 patterns with 3--4 band differences and were related variants \[[@B10]\]. *Spa* types from MSSA isolates differed from those of MRSA. ST22 is the clone most resistant to antibiotics with resistance to gentamicin and erythromycin, in MRSA as well as MSSA, both in carriers and infected patients. This clone was *agr* type I, capsular type 5, *PVL* and *egc* positive.

CC1-ST772
---------

This is the second major clone present in our collection detected in 19% of the isolates both in carrier and disease isolates. Methicillin resistance was detected in 69% in both groups and the isolates had a SCC*mec* V element. Isolates with resistance to gentamicin and erythromycin were found in MRSA only, but both in carriers and infected patients. *Spa* types from MSSA isolates differed from MRSA. This clone was *agr* type II, capsular type 5, *PVL* and *egc* positive.

CC121-ST120 and ST121
---------------------

The ST120/121 clones were detected in 10% of the isolates both in carriers and patients. Methicillin resistance as well as resistance to other antibiotics was not detected in any of the isolates. This clone was *agr* type IV, capsular type 8, *PVL* and *egc* positive.

ST672
-----

We are reporting a new sequence type from India, which appears to have the potential to be a founder clone. This clone was detected in 6% of the isolates in both carrier and disease isolates. Methicillin and gentamicin resistance was detected in 2 disease isolates with a SCC*mec* V element. *Spa* types from MSSA isolates differed from those of MRSA. This clone was *agr* type I, capsular type 8, *PVL* negative and *egc and seb* positive.

CC8-ST1208 and ST72
-------------------

ST1208 is a new single locus variant (SLV) of ST8 and ST72 is a double locus variant (DLV). One ST1208 isolate was *PVL* positive. All three ST1208 MRSA isolates and one ST72 MSSA isolate were resistant to gentamicin and erythromycin. These clones were *agr* type I, and capsular polysaccharide type 5.

CC30-ST30 and ST39
------------------

CC30 was represented by 4 isolates from the community and the hospitals belonging to ST30 and one ST39 carrier isolate (SLV of ST30). Methicillin and erythromycin resistance was detected in one ST30 carrier isolate with SCC*mec* type IVc. All isolates were *agr* type III. This is the only SCC*mec* type IVc isolate belonging to *agr* type III in our collection with a distinct PFGE pattern different from EMRSA-15. Except for one carrier ST39 MSSA isolate, all isolates were *PVL* and *egc* positive and belonged to capsular polysaccharide type 8.

CC398-ST291
-----------

This is the first report of two carrier MSSA isolates which are related to *S. aureus* from bovine origin. ST291 is a DLV of ST398 and *spa* types t937 and t3096 differed by one repeat unit. No antibiotic resistance was detected. PFGE patterns of these two isolates were very closely related with one band difference. These two isolates contained exotoxin D (*etD*) and *edinB* (epidermal cell differentiation inhibitor B) unlike other isolates and were negative for *PVL* and *tst* and contained capsular polysaccharide type 5.

CC45-ST45, CC5-ST5, CC15-ST199, ST6 and ST7
-------------------------------------------

These five other STs included 14 isolates with various characteristics. Methicillin resistant isolates were not detected among these STs, as well as other antibiotic resistance determinants. The *PVL* genes were detected in two isolates. While ST6, 7, 45, and 199 had capsular polysaccharide type 8, CC5 contained type 5.

Differences in SCC*mec* elements of MRSA isolates
-------------------------------------------------

Table [2](#T2){ref-type="table"} represents the PCR and microarray data for all MRSA (A) and representative carrier and disease isolates belonging to SCC*mec* type IV and V (B and C) respectively. After determination of *mecA* gene in all 68 samples, multiplex PCRs were performed for determination of the *mec* and *ccr* complexes using primers for amplification of *ΔmecR1, IS1272, dcs, ccrA2B2, ccrC*, *mec* C2 complex, subtypes of SCC*mec* type IV from IVa to IVd and IVh only for MRSA isolates. Various regions of SCC*mec* type V element from known sequences were also amplified by PCR to further identify SCCmec type V isolates.

###### 

**Characteristics of representative SCC *mec* type IV and V isolates examined by PCR and Microarray**

  **A PCR**        **ST/\# isolates**   ** *mec A* **   ** *Δmec R* **   ** *ccr A2* **   ** *ccr B2* **   ** *dcs* **    ** *IS 1272* **   ** *ccrC* **       ** *mecC2. com* **      ** *PVL* **   ** *hsd S* **   ** *hsdR* **   ** *hsdM* **
  ---------------- -------------------- --------------- ---------------- ---------------- ---------------- -------------- ----------------- ------------------ ----------------------- ------------- --------------- -------------- --------------
                   **22/13**            \+              \+               \+               \+               \+             \+                \-                 \-                      \+            \-              \-             \-
                   **772/9**            \+              \-               \-               \-               \-             \-                \+                 \+                      \+            \-              \+             \+
                   **1208/3**           \+              \-               \-               \-               \-             \-                \+                 \+                      \-            \-              \-             \+
                   **672/2**            \+              \-               \-               \-               \-             \-                \+                 \+                      \-            \-              \+             \+
  **B PCR + MA**   **ST/\# isolates**   ** *mecA* **    ** *ΔmecR* **    ** *Ccr A2* **   ** *ccr B2* **   ** *ccrC* **   ** *PVL* **       ** *Agr type* **   ** *sea* **             ** *seb* **   ** *sec* **     ** *sed* **    ** *see* **
                   **22/5**             \+              \+               \+               \+               \-             \+                **I**              \-                      \-            \-              \-             \-
                   **772/2**            \+              \-               \-               \-               \+             \+                **II**             \+                      \-            \+              \-             \-
                   **1208/3**           \+              \-               \-               \-               \+             \-                **I**              \+                      \+            \-              \-             \-
                   **672/1**            \+              \-               \-               \-               \+             \-                **I**              \-                      \-            \-              \-             \-
  **C MA**         **ST/\# isolates**   ** *blaZ* **    ** *blaI* **     ** *blaR* **     ** *hlb* **      ** *sak* **    ** *chip* **      ** *scn* **        ** *ccrC\* (ZH47)* **   ** *Egc* **   ** *splA* **    ** *splB* **   ** *splE* **
                   **22/5**             \+              \+               \+               \+               \+             \+                \+                 \-                      \+            \-              \-             \-
                   **772/2**            \+              \+               \+               \-               \-             \-                \+                 \+                      \+            \-              \-             \-
                   **1208/3**           \+              \+               \+               \+               \+             \-                \+                 \-                      \-            \+              \+             \+
                   **672/1**            \+              \+               \+               \+               \+             \-                \+                 \+                      \+            \-              \-             \-

\* Second *ccr C* present in SCC*mec*ZH47.

Isolates carrying SCC*mec* type IV cassettes did not amplify primers specific for IVa, IVb, IVc, IVd and IVh. Previous work from our laboratory has shown several variants of classical EMRSA-15 in PFGE patterns, and the J regions could be different from the known ST22, EMRSA-15 isolates \[[@B10]\]. One ST30 carrier isolate carrying SCC*mec* type IV has a different PFGE pattern from that of ST22 (Figure [2](#F2){ref-type="fig"}) and amplified primers specific for SCC*mec* type IVc.

Differences in type V SCC*mec* elements
---------------------------------------

SCC*mec* type V elements were present in three different classes of STs-772, 672 and 1208. PCRs to identify different regions of type V elements (using strain WIS (WBG8318), Genbank accession no. AB121219) and microarray of selected isolates pointed to two different variants of type V element as shown in Table [2](#T2){ref-type="table"} (B and C). *CcrC, mecA* and *ugpQ* (Glycerophosphoryl-diester-Phosphodiesterase next to *mecA*) were present in all type V isolates while only isolates belonging to ST772 and ST672 carried a second *ccrC* region in the SCC*mec*ZH47 in the microarray from the mosaic cassette ZH47 reported by Heuser et al \[[@B15]\]. This region was positive by PCR using primers specific for the second *ccrC* in the SCC*mec*ZH47 region with a size of 435 bp and is identical in sequence to isolates containing composite cassettes of SCC*mec* type V (5&5 C2). Type V isolates belonging to CC8 did not carry the second *ccrC* region. SCC*mec*ZH47 also contain *ccrA2ccrB2* and a very small truncated *mecR* region which did not amplify in our ST772 and ST672 isolates by PCR and microarray. Apart from amplifying the *mec*C2 complex upstream of *mecA*, none of the primers designed for several different regions of SCC*mec* type V based on sequences from WIS strain, amplified DNA from our type V isolates indicating that the J regions could be different. All isolates belonging to ST672 and 772 amplified primers for both *hsdR* and *hsdM* regions while ST1208 isolates did not amplify the *hsdR* region indicating there could be changes in this region as well (Table [2](#T2){ref-type="table"}A). No DNA fragments targeting hsdS, which determine the specificity of restriction modification system, were amplified with DNAs of all isolates. The other genes indicated in Table [2](#T2){ref-type="table"}C are selected from the microarray data to examine the differences among isolates belonging to different STs.

Discussion
==========

We have characterized *S. aureus* isolates from different cities in India, which belong to a wide variety of STs from healthy carriers and individuals with simple to complicated diseases. Even in a small number of isolates (68), there were 15 different STs (including the two isolates resembling *S. aureus* from animal origin) and MSSA isolates were the most diverse. Among the MRSA isolates, the predominant ST were 22, 772, 672, 8 and 30. ST672 is a new emerging clone with only two isolates reported from Australia and U.S. While EMRSA-15 (ST22) appeared as a major clone in Indian hospitals with SCC*mec* type IV element, ST772, 672 and 8 are emerging as SCC*mec* type V. It is evident from our studies that at least two different types of SCC*mec* type V elements exist in isolates belonging to three distinct STs.

The most obvious bias in the study is the limited number of isolates collected, but our results are in part concordant with those in the literature: the two major MRSA STs (STs22 and STs772) reported earlier in India \[[@B9],[@B11]\]. Many of the other MSSA and two of the MRSA STs are being reported for the first time.

The antibiotic sensitivity data (not shown) indicates that majority of carrier MSSA were sensitive to all five tested antibiotics. Antibiotic resistant determinants were found mainly in carrier and disease MRSA isolates, but few ST22 carrier and disease MSSA isolates also had resistance determinants for gentamicin and /or erythromycin. For few MRSA isolates (STs 22, 772, 672, and 8) containing the *mec*A gene, MICs for oxacillin and cefoxitin were 4--8 and 8-16 μg/ml respectively while for most other isolates the corresponding values were 8--16 and 16-32 μg/ml (data not shown). We considered these isolates as methicillin resistant as the patient treatment with oxacillin would select for resistance in a heterogeneous population containing the *mecA* gene. Similar MRSA isolates of ST59 background were found in Taiwan \[[@B16]\] and CC5 lineage in Switzerland among injection drug users. One of the Swiss isolates of CC5 (ZH47) has been reported to have low MIC for oxacillin and sequenced to contain a composite SCC*mec* cassette with ZH47 region containing a second *ccrC*. Our isolates of ST772 and ST672 with low level of oxacillin resistance also contain the second *ccrC* region. The low level of resistance has been attributed to mutations in the *mecA* promoter region \[[@B17]\].

EMRSA-15 (ST22) has been reported to be replacing HA-MRSA in hospitals in many countries - Germany, Portugal, Singapore, to name just a few \[[@B18]-[@B20]\]. In 2003 when we had collected MRSA isolates from Indian hospitals \[[@B7],[@B8]\], majority of them belonged to ST239 with SCC*mec* type III or IIIA; ST22 now made up 28% of the total in the present collection. A study from Mumbai, India, with larger sample numbers, from a tertiary care hospital also indicates that EMRSA-15 is replacing type III SCC*mec* containing isolates \[[@B11]\].

ST772 (CC1) has been reported from India, Bangladesh and Malaysia \[[@B9],[@B12],[@B13]\]. Our ST772 isolates and that from Bangladesh have *agr* type II while CC1 isolates from Malaysia, Australia and U.S. have been reported to be *agr* type III. Aires de Sousa et al., have reported three sequence types (ST188, ST573, ST1) belonging to CC1, as *agr* types I, II, and III respectively in a survey of isolates from Portuguese hospitals and community \[[@B21]\]. CC1 lineage itself seems to be changing from an independent founder to a sub-founder and CC15 is evolving as the founder strain from the eBURST analysis (Figure [1](#F1){ref-type="fig"}). ST573 appears to be the link between the founder and sub-founder clones. CC1 appears to be evolving along with the *agr* locus rapidly with numerous recombinations which is unusual, as *agr* types are usually uniform in a CC.

ST672 has not been reported from any of the Asian countries till now. The MLST data base reports one isolate from Australia and one from U.S. It appears important to determine if this clone will persist as a minor clone or not. ST772 and ST672 MRSA isolates carried the same composite type V SCC*mec* elements unlike the ones carried by ST1208 isolates (Table [2](#T2){ref-type="table"}). Among the numerous results obtained by the microarrays, collagen binding adhesion (*cna*) was absent in ST672 and present in 772 (raw data of microarray provided). The capsular polysaccharide types 8 and 5 were present in ST672 and 772 respectively.

The large diversity in the STs present in the MSSA isolates confirmed the highly diverse MSSA population reported from Shanghai, China, recently which included ST5, 6, 7, 30 and 121 isolates along with others \[[@B22]\]. The probability of MSSA conversion to MRSA is perhaps high in India with the over use of antibiotics and its spread due to inadequate hygienic practices.

High prevalence of *PVL* and *egc* among the Indian MSSA and MRSA isolates is unlike the situation in Bangladesh, and Indonesia where only MSSA isolates contain PVL \[[@B12],[@B23]\]. This indicates a possibility of *PVL* positive MSSA acquiring SCC*mec* elements to become *PVL* positive MRSA although this needs to be confirmed. A combination of *PVLegc* along with other entero-toxins could increase the severity of diseases caused by *S. aureus* although the role of *PVL* and other toxins is not completely elucidated \[[@B24],[@B25]\]. There were no differences in the presence of the different virulence factors we characterized among the carrier isolates or the patient isolates.

Conclusion
==========

This paper reports detailed molecular analysis of *S. aureus* isolates collected from different Indian cities and environments with their virulence factors for the first time. We have identified new and emerging STs as MRSA in addition to already reported ones in healthy carriers as well as patients. There are variant types of type IV and V SCC*mec* elements among MRSA. There is more diversity among the STs found in MSSA which may have the potential to acquire methicillin resistance. Majority of these isolates are *PVL* and *egc* positive. The detailed analysis of virulence factors might help in understanding of diseases caused and influence of host factors in those diseases.

Methods
=======

Isolates and patients
---------------------

Sixty eight *S. aureus* isolates were included in this study, 38 from healthy nasal carriers and 30 from infection sites. Isolates collected from nasal carriers from rural community and urban population between 2006 and 2008 were cultured. Carriers had no identified risk factors for MRSA acquisition which included prior hospitalization, use of antibiotics, and surgeries in the past year. Nasal swabs were collected after explaining the prepared questionnaire and with consent of the subjects. Isolates recovered from infected sites were from wounds, pleural fluid and blood cultures collected in patients from hospitals in Bengaluru, Mumbai, Delhi, and Hyderabad. Data on community origin of these isolates is limited to a few as the isolates were sent to us from physicians from different hospitals. Ethical clearances and written consents for publication were obtained from the respective hospitals.

Phenotypic characterization
---------------------------

*S. aureus* isolates were selected after growth on chromogenic agar medium (chromAgar, bioMérieux, Marcy-L'Etoile, France) and identified after characterization by Gram staining, detection of catalase, coagulase and DNAse as described elsewhere \[[@B26]\].

Antibiotic susceptibility testing
---------------------------------

Susceptibility testing was performed by Kirby-Bauer disc diffusion according to the guidelines recommended by the CLSI (formerly NCCLS) on Mueller-Hinton agar plates at 37°C using antibiotic discs. Minimum Inhibitory Concentration (MIC) for oxacillin and cefoxitin was determined by the broth dilution method in Mueller-Hinton Broth after 24 hrs of incubation at 37°C in micro titer plates \[[@B27]\].

Chromosomal DNA isolation
-------------------------

Chromosomal DNA was extracted according to previously published procedures using lysostaphin \[[@B7]\].

PCR for detection of SCC*mec* elements and *ccr* types
------------------------------------------------------

SCC*mec* typing by determination of *mec* and *ccr* complexes for types IV and V SCC*mec* elements was carried out by multiplex PCR \[[@B28]-[@B30]\]. Subtyping of type IV SCC*mec* was performed according to the procedure of Zhang et al and Milherico et al \[[@B31],[@B32]\].

Identification of accessory gene regulator (*agr)* alleles by PCR
-----------------------------------------------------------------

The four *agr* alleles were determined by a multiplex PCR as described in Gilot et al \[[@B33]\].

Detection of toxins
-------------------

The presence of *PVL* genes was detected by PCR using the published primers and procedure \[[@B34]\]. Presence of staphylococcal entero-toxins A, B, C, D and E, exfoliating toxins A and B and toxic shock syndrome toxin *tst* (TSST-1) and enterotoxin gene cluster (*egc*) cluster were detected by several multiplex PCRs using published procedures \[[@B35],[@B36]\].

MLST and *spa* typing
---------------------

MLST and *spa* typing were done as described earlier \[[@B37],[@B38]\].

PFGE
----

PFGE was performed as described before \[[@B7]\].

eBURST analysis
---------------

Clonal relationship of the isolates was determined by using eBURST v3 program with the entire MLST database.

Microarray Analysis using CLONDIAG®
-----------------------------------

Microarray was performed for selected isolates from each of the clonal complexes. Diagnostic DNA microarray based on the Array/Tube platform (CLONDIAG, Jena, Germany) were utilized as described by Monecke et al \[[@B14]\]. The micro-array covers 185 distinct genes and about 300 alleles there of, including species- specific controls, *agr* alleles, genes including virulence factors, and microbial surface components recognizing adhesive matrix molecules (MSCRAMMS), capsule- type specific genes, as well as resistance determinants and immune evasion factors.
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